NCT06411457View on ClinicalTrials.gov

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2026

Conditions
Breast Cancer
Interventions
DRUG

SHR-A1811+Adebrelimab

Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt

Trial Locations (1)

00

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER